Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/10604/Bekoz-H%c3%bcseyin-2022.pdf.jpg?sequence=4&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2022Yazar
Ferhanoğlu, BurhanGülbaş, Zafer
Uzay, Ant
Özcan, Muhit
Özkalemkaş, Fahir
Dal, Mehmet Sinan
Kalyon, Hakan
Akay, Olga Meltem
Deveci, Burak
Bekoz, Hüseyin
Sevindik, Ömür Gökmen
Toptaş, Tayfur
Yılmaz, Asu Fergün
Koyun, Derya
Alkış, Nihan
Birtaş Ateşoğlu, Elif
Üst veri
Tüm öğe kaydını gösterKünye
Ferhanoğlu, B., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F., Dal, M. S. ... Birtaş Ateşoğlu, E. (2022). Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data. Blood içinde (6704-6705. ss.). https://doi.org/10.1182/blood-2022-165385Özet
Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T
cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response (CR) following
firstline treatment with rituximab and chemotherapy, about 40% of patients with diffuse large B-cell lymphoma (DLBCL) is
refractory or relapse (R/R). Autologous stem-cell transplantation (ASCT) can cure some of these patients but many patients
cannot undergo this procedure. CAR-T therapies are a significant advance but not available in many countries like Turkey. In
Phase II expansion study, the overall response rate (ORR) was 51.6% and complete remission (CR) rate was 39.4% in R/R
DLBCL patients (Dickinson er al. JCO 2022). In this retrospective study, we aimed to report the outcomes of patients who used
glofitamab via compessionate use in Turkey.
WoS Q Kategorisi
Q1Kaynak
BloodCilt
140Sayı
Supplement: 1Koleksiyonlar
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6677]